Small Business Innovation Research (SBIR) program, Phase I
Agency: Administration for Community Living
- 93.433 -- ACL National Institute on Disability, Independent Living, and Rehabilitation Research
Forecasted opportunityLast Updated: Sep 25, 2026
Important dates
- Forecasted post date: October 16, 2026
- Forecasted application due date: December 16, 2026
- Forecasted award date: June 1, 2027
- Forecasted project start date: June 1, 2027
- Fiscal Year: 2027
Award details
- Expected project funding: $1,100,000
- Expected awards: 11
Award min.
$95,000
Award max.
$100,000
- Funding opportunity number:HHS-2027-ACL-NIDILRR-BISA-0308
- Cost sharing or matching requirement:No
- Funding instrument type:
- Grant
- Opportunity Category:Discretionary
- Opportunity Category Explanation:Not specified
- Category of Funding Activity:
- Science technology and other research and development
- Category Explanation:Not specified
History
- Forecast posted date: September 25, 2026
- Archive date: September 30, 2027
- Version: 1
Summary
The purpose of the Federal SBIR program is to stimulate technological innovation in the private sector, strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs, and improve the return on investment from Federally-funded research for economic and social benefits to the nation. The specific purpose of ACL's SBIR program is to improve the lives of people with disabilities through R/R&D products generated by small businesses, and to increase the commercial application of ACL-supported research results and development products. Phase I SBIR grants are intended to conduct research to determine the scientific or technical merit and feasibility of concepts, topics, or ideas. NIDILRR will make 11 grants under this opportunity. Grants will have a 6-month project period with a corresponding six-month budget period.
Eligibility
Business
- Small businesses
Additional information on eligibility
Documents
No documents are currently available.
Agency contact information
Email: brian.bard@acl.hhs.gov
brian.bard@acl.hhs.gov
